DFTX Share Price Performance
US$37.73
28.08 (290.98%)
44.1% undervalued intrinsic discount
US$67.47
Fair Value
Price US$37.73
AnalystConsensusTarget US$67.47
AnalystLowTarget US$52.00
AnalystHighTarget US$72.73
Fair ValueUS$67.47
Share Pricen/a
Definium Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 103 Fair Values set on narratives written by author
DFTX Community Narratives
AN
Fair Value
·Fair Value US$67.47 44.1% undervalued intrinsic discount
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
Fair Value
·Fair Value US$52 27.4% undervalued intrinsic discount
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$72.73 48.1% undervalued intrinsic discount
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Definium Therapeutics
44.1% undervalued intrinsic discount
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
View narrativeAN
Updated 21 Aug
Definium Therapeutics
27.4% undervalued intrinsic discount
Updated
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
View narrativeAN
Updated 4 Sep
Definium Therapeutics
48.1% undervalued intrinsic discount
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
View narrativeAN
Updated 10 Jul
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
DFTX: Phase 3 Mood Disorder Wins And Psychedelic Policy Should Drive Returns
Fair Value: US$52 27.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DFTX: Phase 3 Mood Disorder Data Will Recast Psychedelic Treatment Potential
Fair Value: US$67.47 44.1% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DFTX: Phase 3 Depression Data Will Drive Repricing Of Psychedelic Franchise
Fair Value: US$72.73 48.1% undervalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Definium Therapeutics, Inc. Key Details
About DFTX
- Founded
- n/a
- Employees
- 106
- CEO
- WebsiteView website
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
